How IFN Signaling Tunes Macrophage Mitochondria in Inflammation Resolution

Why It Matters

Decoding the IFN‑I‑mitochondrial link provides a target to enhance antiviral treatments while minimizing inflammatory side effects, a critical need in cancer and infectious disease therapeutics.

Key Takeaways

• IFN‑I lowers macrophage mitochondrial membrane potential
• ISG15 binds mitochondria, boosts ATP production
• Reduced MMP triggers mitochondrial fission, enhancing efferocytosis
• ISG15 deficiency impairs dead‑cell clearance
• Axis offers target to refine interferon therapies

Pulse Analysis

Type‑I interferons are central to antiviral defense, yet their clinical use has been hampered by unpredictable inflammatory outcomes. The CNIC team uncovered a metabolic conduit that translates IFN‑I signals into precise mitochondrial adjustments in macrophages. By engaging the interferon‑α/β receptor, IFN‑I induces the ubiquitin‑like protein ISG15, which docks onto mitochondrial proteins, subtly lowering membrane potential while driving ATP synthesis. This dual effect reshapes the organelle’s architecture, promoting fission that readies the cell for heightened phagocytic activity.

The metabolic reprogramming has tangible functional benefits. Lowered membrane potential activates a protease cascade that fragments mitochondria, a change linked to increased efferocytosis—the clearance of dying cells that fuels tissue repair. In animal models, IFN‑I‑treated macrophages displayed superior uptake of apoptotic debris, a capability that vanished when ISG15 was knocked out. Simultaneously, the altered mitochondrial state dampens expression of inflammatory genes, establishing a feedback loop that tempers excessive interferon signaling and averts autoinflammatory risk.

Clinically, the IFN‑I‑ISG15 mitochondrial axis opens avenues for more nuanced immunotherapies. By fine‑tuning ISG15 activity or mimicking its mitochondrial effects, drug developers could amplify the beneficial anti‑viral and anti‑tumor actions of interferons while curbing collateral inflammation. Moreover, the pathway’s relevance to mitochondrial dynamics suggests broader applications in diseases where defective clearance of cellular debris drives pathology, such as chronic viral infections, autoimmune disorders, and certain cancers. Harnessing this axis may therefore accelerate the resolution of inflammation across multiple therapeutic landscapes.